Featured Research

from universities, journals, and other organizations

Ulcerative Colitis Treatment Reduces Need For Surgery By Almost Half, Study Suggests

Date:
October 1, 2009
Source:
Mayo Clinic
Summary:
A new study has found that ulcerative colitis patients had a 41 percent reduction in colectomy after a year when treated with infliximab.

A new study led by Mayo Clinic researchers has found that ulcerative colitis patients had a 41 percent reduction in colectomy after a year when treated with infliximab, according to a study published in the October 2009 issue of Gastroenterology.

Ulcerative colitis, an inflammatory bowel disease (IBD) that causes chronic inflammation of the colon, is characterized by abdominal pain and diarrhea. Like Crohn's disease, another common IBD, ulcerative colitis can be debilitating and often lead to colectomy or surgical removal of the colon.

"Our purpose in this study was to see if the use of infliximab for ulcerative colitis would reduce the need for surgery," says William Sandborn, M.D., a Mayo Clinic gastroenterologist and lead author of the study. "We found that treatment with infliximab reduced the need for colectomy by 41 percent compared to patients treated with placebo."

In this multi-center, international study, 728 patients received placebo or infliximab (5 or 10 mg/kg) for 46 weeks and were monitored for hospitalization or surgical outcomes. Eighty-seven percent (630 of 728) had complete follow-up for the endpoint of whether or not they had colectomy, while the remaining 13 percent (98 of 728) of patients had follow-up for less then a year, with a median follow-up of 6.2 months in these patients. The research showed that treatment with infliximab at 0, 2 and 6 and then every 8 weeks reduced the incidence of colectomy through 54 weeks by 41 percent in outpatients with moderately-to-severe active ulcerative colitis.

The cumulative incidence of colectomy through 54 weeks was 10% for infliximab and 17% for placebo (p=0.02). Compared with placebo, fewer ulcerative colitis-related hospitalizations and surgeries/procedures occurred with infliximab therapy.

"One of the most feared outcomes for ulcerative colitis patients is surgical removal of the colon," says Dr. Sandborn. "Our research hopes to provide other treatment solutions for patients beyond surgery."

Previous research has shown that infliximab therapy induced clinical remission and bowel healing for colitis patients. This new research provides more information and options for patients struggling with this difficult disease, explains Dr. Sandborn.

Infliximab is an artificial antibody that works by blocking tumour necrosis factor alpha (TNF alpha). TNF alpha is a chemical messenger and a key part of the immune reaction. Infliximab blocks the action of TNF alpha by preventing it from binding to its receptor in the cell.

Ulcerative colitis usually affects only the inner lining of the large intestine (colon) and rectum. It usually occurs in a continuous stretch of the colon, unlike Crohn's disease, which occurs in patches anywhere in the digestive tract and often spreads into the deeper layers of affected tissues.

Dr. Sandborn provided consulting services for Centocor during the course of this research and received no personal compensation. Mayo Clinic received reimbursement for the services provided by Dr. Sandborn.


Story Source:

The above story is based on materials provided by Mayo Clinic. Note: Materials may be edited for content and length.


Cite This Page:

Mayo Clinic. "Ulcerative Colitis Treatment Reduces Need For Surgery By Almost Half, Study Suggests." ScienceDaily. ScienceDaily, 1 October 2009. <www.sciencedaily.com/releases/2009/10/091001081215.htm>.
Mayo Clinic. (2009, October 1). Ulcerative Colitis Treatment Reduces Need For Surgery By Almost Half, Study Suggests. ScienceDaily. Retrieved April 16, 2014 from www.sciencedaily.com/releases/2009/10/091001081215.htm
Mayo Clinic. "Ulcerative Colitis Treatment Reduces Need For Surgery By Almost Half, Study Suggests." ScienceDaily. www.sciencedaily.com/releases/2009/10/091001081215.htm (accessed April 16, 2014).

Share This



More Health & Medicine News

Wednesday, April 16, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Could Even Casual Marijuana Use Alter Your Brain?

Could Even Casual Marijuana Use Alter Your Brain?

Newsy (Apr. 16, 2014) A new study conducted by researchers at Northwestern and Harvard suggests even casual marijuana use can alter your brain. Video provided by Newsy
Powered by NewsLook.com
Formerly Conjoined Twins Released From Dallas Hospital

Formerly Conjoined Twins Released From Dallas Hospital

Newsy (Apr. 16, 2014) Conjoined twins Emmett and Owen Ezell were separated by doctors in August. Now, nearly nine months later, they're being released from the hospital. Video provided by Newsy
Powered by NewsLook.com
Ebola Outbreak Now Linked To 121 Deaths

Ebola Outbreak Now Linked To 121 Deaths

Newsy (Apr. 15, 2014) The ebola virus outbreak in West Africa is now linked to 121 deaths. Health officials fear the virus will continue to spread in urban areas. Video provided by Newsy
Powered by NewsLook.com
Cognitive Function: Is It All Downhill From Age 24?

Cognitive Function: Is It All Downhill From Age 24?

Newsy (Apr. 15, 2014) A new study out of Canada says cognitive motor performance begins deteriorating around age 24. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins